Posts filtered by tags: Life Sciences[x]


 

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a specific genetic signature.Johnson said it was Kipps’ work, which identified ROR1 as a promising cancer protein to target and developed a drug candidate that ap...
Tags: Startups, Cancer, Funding, Trends, Venture Capital, San Diego, Astrazeneca, Abbvie, Johnson, Biotech, Financing, Life Sciences, Clinical Trials, Gilead Sciences, Citadel, UC San Diego


Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add multiple sclerosis and neuroinflammation to their ongoing partnership.The alliance came to New York-based Bristol (NYSE: BMY) via its acquisition of Celgene last year. The original 2017 deal covered the development of up to four blood cancer drugs. The partnership expanded the following year to cover four more drug targets. As of last November, Celgene had opte...
Tags: Deals, Startups, New York, Boston, Cancer, Trends, Merck, Multiple Sclerosis, Infectious Disease, Immunotherapy, Abbvie, Biotech, Life Sciences, Autoimmune Diseases, Celgene, Waltham


Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s

[Updated, 4:54 p.m.] Amylyx Pharmaceuticals’ two-pronged approach to neurodegenerative diseases has shown promise in amyotrophic lateral sclerosis (ALS) testing and the company now has $30 million to complete a separate clinical trial in Alzheimer’s disease.The Series B round of financing announced Wednesday was led by Morningside Ventures, a firm that had previously invested in the Cambridge, MA-based biotech.Amylyx’s experimental therapy, AMX0035, is a proprietary combination of two compounds...
Tags: Deals, Startups, Boston, Trends, Neuroscience, Investing, Alzheimer's Disease, Cambridge, Fda, Biotech, Morningside Ventures, Life Sciences, Clinical Trials, National blog main, Boston blog main, Boston top stories


Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases

The blood-brain barrier protects the functioning of that essential organ, but it’s also a hurdle to delivering neurological drugs.Italy’s Chiesi Group has agreed to pay Guilford, CT-based Bioasis Technologies $3 million up front to use the preclinical firm’s technology to facilitate the delivery of enzymes across the blood-brain barrier to treat neurological symptoms associated with four lysosomal storage disorders (LSDs). Such diseases are caused by mutations in the genetic instructions for im...
Tags: Deals, Boston, Funding, Trends, Italy, Biotech, Financing, Partnership, Life Sciences, Rare Disease, Alliance, Chiesi, National blog main, New York blog main, Boston blog main, BioMarin Pharmaceuticals


Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage

A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event.Innovation in the San Francisco Bay Area may first bring to mind tech behemoths like Facebook and Google. But some drug development companies in the region say its openness to new ideas and the combination of software experience and life sciences expertise are boosting their prospects.“For us inside t...
Tags: Google, Startups, Facebook, San Francisco, Trends, Tech, People, Innovation, Biotech, Life Sciences, Healthtech, San Francisco Bay Area, Daphne Koller, San Francisco blog main, SanFranciscoVC, TwoXAR


Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs

Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins.Now the Cambridge, MA, biotech is looking to tap the public markets to bulk up company coffers and get its two lead drug candidates into mid-stage clinical trials as potential treatment for cancers.In documents filed Wednesday with regulators, Relay set a preliminary target of $200 million for its IPO. The company is looking...
Tags: Startups, Ipo, Boston, Cancer, Softbank, Funding, Trends, Venture Capital, Cambridge, Biotech, Financing, Life Sciences, Renaissance Capital, National blog main, Boston blog main, National top stories


La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War

It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical.San Diego-based La Jolla (NASDAQ: LJPC) has pledged to pay Tetraphase shareholders $43 million in cash now plus another $16 million tied to sales goals for Tetraphase (NASDAQ: TTPH) antibiotic eravacycline (Xerava). That beats the $39 million in upfront cash a...
Tags: Deals, Trends, San Diego, Fda, Biotech, Antibiotics, Life Sciences, Clinical Trials, National blog main, Boston blog main, San Francisco blog main, Boston top stories, San Diego blog main, San Diego top stories, Urinary Tract Infections, LJPC


AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

The body’s natural process for healing wounds has led AsclepiX Therapeutics to a novel approach to treating diseases of the eye. The startup is now gearing up to test its technology in humans, and it has raised $35 million in Series A financing to support its research.Cuts and scrapes in the skin spark the formation of new blood vessels and connective tissue that fills the wound. But this process, called angiogenesis, does not continue indefinitely. Within days the body returns to a state of eq...
Tags: Deals, Startups, Trends, Investing, It, Software, National, Biotech, Life Sciences, Bayer, Clinical Trials, Roche, Johns Hopkins University, Ranibizumab, Regeneron Pharmaceuticals, Diabetic Macular Edema


Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx

Cancer treatment is increasingly moving toward targeted therapies based on the genetics of a patient’s tumor and Invitae is ensuring it gets its share of this growing market with a deal to acquire precision oncology startup ArcherDx.San Francisco-based Invitae announced Monday that it has agreed to pay $886 million for ArcherDx—$325 million in cash plus $561 million in Invitae shares at $18.71 apiece, which was Friday’s closing price. Shareholders of privately held ArcherDx could earn up to $50...
Tags: Deals, Startups, Cancer, San Francisco, Trends, Investing, Astrazeneca, Biotech, Illumina, Life Sciences, Casdin Capital, National blog main, National top stories, San Francisco blog main, San Francisco top stories, Jason Myers


Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire sector.Royalty Pharma (NASDAQ: RPRX) acquires the royalty rights for drugs. Most of those royalties are for products that are already approved, but the company has also been striking deals for compounds still in development. The biotechs forking over royalty rights get cash right away to continue the expensive...
Tags: Deals, Startups, Ipo, Trends, Neuroscience, Investing, Merck, Inflammatory Bowel Disease, National, GlaxoSmithKline, Allergan, Abbvie, Oxford University, Biotech, Vaccines, Liver disease


Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better

Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy approach has saved countless lives and turned drugs from Merck and Bristol Myers Squibb into blockbuster products.But what if a single drug could block checkpoint proteins while simultaneously sparking an anti-tumor response? That’s what Shattuck Labs aims to do. Its lead asset is in development under a partnership with Takeda Pharmaceutical (N...
Tags: Deals, Startups, Cancer, Trends, Investing, Merck, GlaxoSmithKline, Biotech, Life Sciences, Clinical Trials, Amgen, Bristol-myers Squibb, Gilead Sciences, Laurene Powell Jobs, Takeda Pharmaceutical, National blog main


Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug

Alpine Immune Sciences’ lupus drug candidate now has AbbVie lined up to continue the compound’s development.The drug, ALPN-101, is ready for Phase 2 testing, which will be conducted by Seattle-based Alpine. The deal announced Thursday grants AbbVie (NYSE: ABBV) an exclusive option to license the drug after that study. The North Chicago, IL-based pharmaceutical company is paying its new partner $60 million up front for that option and, if the drug achieves clinical and regulatory milestones, wil...
Tags: Deals, Cancer, Trends, Fda, Allergan, Abbvie, Biotech, Seattle, Immunology, Life Sciences, Autoimmune Diseases, Clinical Trials, Lupus, North Chicago, National blog main, Seattle blog main


Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs

Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies.Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire Series A funding from a sole source: Nan Fung Life Sciences, a subsidiary of Hong Kong property developer Nan Fung Group.The round, raised by an eight-person company with one preclinical asset, is a bet on Del Mar, CA-base...
Tags: Startups, Hong Kong, Funding, Trends, Neuroscience, Investing, Venture Capital, San Diego, Deal, Astrazeneca, Novartis, Allergan, Abbvie, Biotech, Financing, Life Sciences


Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies

The cancer cell therapies available today are made by tweaking a patient’s own immune cells to better recognize and fight the disease. Orca Bio is developing what it says is the next generation of cell therapy: custom preparations made without modifying cells or genes.Orca is already testing its technology in humans, though it has kept that research mostly under wraps. As the startup prepares to reveal its preliminary findings and ramp up its manufacturing capability, the Menlo Park, CA-based b...
Tags: Deals, Startups, Cancer, San Francisco, Trends, Investing, Novartis, Biotech, Stem Cell, Lightspeed Venture Partners, Stanford University, Life Sciences, Clinical Trials, Gilead Sciences, Menlo Park CA, Irv Weissman


Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer

Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing.The San Diego-based company says it will use the money to accelerate its antibody programs, including asking the FDA for the green light to move its lead drug candidate into the clinic sometime next year. Lassen was started last year within Frazier Healthcare Partners; Mark Barrett, an entrepreneur in residence at ...
Tags: Deals, Startups, Cancer, Funding, Trends, Venture Capital, San Diego, Fda, Biotech, Financing, Lassen, Life Sciences, Northern California, Frazier, CSL, Frazier Healthcare Partners


GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance

GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug class through a research alliance with Ideaya Biosciences that spans three of the biotech’s programs, all slated to reach clinical trials in the next three years.According to deal terms announced Tuesday, GSK (NYSE: GSK) has agreed to pay Ideaya (NASDAQ: IDYA) $100 million in cash up front. The pharmaceutical giant is also making a $20 million ...
Tags: Deals, Cancer, San Francisco, Trends, Fda, GlaxoSmithKline, Biotech, Life Sciences, Clinical Trials, GSK, National blog main, Boston blog main, National top stories, San Francisco blog main, San Francisco top stories, Boston top stories


Bit Bio’s “enter button for the keyboard to the software of life” nabs the company $41.5 million

Bit Bio, the new startup which pitches itself as the “enter button for the keyboard to the software of life” only needed three weeks to raise its latest $41.5 million round of funding. Originally known as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based company was founded by Mark Kotter in 2016 to commercialize technology that can reduce the cost and increase the production capacity for human cell lines. These cells can be used in targeted gene therap...
Tags: TC, Biology, Cancer, Tech, United Kingdom, Stem Cells, Cambridge, Disease, Cambridge University, Director, Operating System, Crispr, Biotechnology, Founder, Life Sciences, Juno


Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More

At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization.Instead, attendees from 64 countries spanning 28 times zones convened online this week for the first-ever virtual BIO International Convention. There, topics once as unanticipated as the remote nature of the meeting shared top billing: COVID-19 and racism. Infectious disease experts opined on the industry’...
Tags: Deals, Startups, Trends, Diversity, Merck, Racism, Incubator, Venture Capital, San Diego, M&a, Astrazeneca, National, Pfizer, Vaccine, Abbvie, Biotech


Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia

Diabetes drug giant Novo Nordisk has reached a $725 million deal to acquire Corvidia Therapeutics, a clinical-stage biotech developing treatments for disorders affecting the heart and the kidneys.The upfront payment due to Corvidia shareholders is cash. According to the terms of the agreement, Denmark-based Novo Nordisk (NASDAQ: NOVO) could be on the hook for about three times that much depending on regulatory and sales milestones achieved by the Corvidia drugs. Details of those milestones, whi...
Tags: Deals, Startups, Sofinnova Partners, Boston, Trends, Diabetes, Astrazeneca, Denmark, Biotech, Novo Nordisk, Insulin, Venrock, Life Sciences, Clinical Trials, Novo, National blog main


Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes

Verve Therapeutics aims to use gene editing to address heart attacks by targeting the liver, not the heart. And it wants to make its edits inside the patient. The startup’s approach raises a lot of questions. Verve has some answers now, and it has raised $63 million to learn more.The new financing announced Thursday was led by GV, the same investor that led the Cambridge, MA-based company’s Series A round of funding last year. With the additional cash, Verve CEO Sekar Kathiresan says Verve coul...
Tags: Deals, Startups, Boston, Trends, Investing, Fda, Allergan, Abbvie, Biotech, Crispr, Life Sciences, Editas Medicine, Clinical Trials, Biomatics Capital, ARCH Venture Partners, Gene Editing


Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition

Melinta Therapeutics and Tetraphase Pharmaceuticals, two antibiotics companies that have struggled separately, will now see if they have better luck together.Morristown, NJ-based Melinta has reached a deal to acquire Tetraphase (NASDAQ: TTPH) for $39 million in cash up front. Tetraphase shareholders could earn up to $16 million more if the Watertown, MA-based biotech’s sole commercialized product hits sales targets.An antibiotic developed by Tetraphase, eravacycline (Xerava), was approved in 20...
Tags: Deals, New York, Trends, Biotech, Life Sciences, Watertown, Morristown NJ, National blog main, New York blog main, New York top stories, Boston blog main, Boston top stories, Deerfield Management, Antibiotic, Tetraphase, Tetraphase Pharmaceuticals


CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

When fluid builds up in the brain faster than the body can absorb it, pressure builds sparking what’s called hydrocephalus. Surgery can address this condition, but the decades-old approach to relieving the cranial pressure caused by the fluid is susceptible to failure, says Dan Levangie, CEO and president of CereVasc.Levangie’s medical device startup aims to treat hydrocephalus with a less invasive method that leverages newer technologies now in use for vascular and neurological procedures. As ...
Tags: Deals, Startups, Boston, Trends, Investing, Fda, Hydrocephalus, Biotech, Medical Device, Life Sciences, Abbott Laboratories, Medtronic, Tufts Medical Center, National blog main, New York blog main, New York top stories


Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More

Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect the broad spectrum of patients that drug makers aim to treat.Racial disparities are evident in the COVID-19 pandemic, which is hitting the African American community hardest. Inequality has been thrust front and center following the death of George...
Tags: Deals, Startups, Cancer, Trends, Investing, Merck, Prostate Cancer, Multiple Sclerosis, Alzheimer's Disease, National, Epilepsy, Pfizer, Vaccine, Abbvie, Biotech, Novo Nordisk


Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs

Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are creating new medicines.Atlas revealed Friday that it closed its 12th fund after raising $400 million, a total that pushes the amount the company has raised in recent years to $1 billion. In addition to Fund XXII and its previous fund, for which it raised $350 million in 2017, Atlas last year...
Tags: Deals, Startups, Boston, Funding, Trends, Atlas, Venture Capital, Novartis, Biotech, Financing, Acquisition, Life Sciences, Celgene, Cambridge MA, Atlas Venture, National blog main


Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins

AstraZeneca is looking to bolster its cancer R&D portfolio with therapies that target RNA-modifying enzymes and other proteins involved in cancer. On Thursday the Cambridge, UK-based pharma giant announced it would pay Boston-area biotech Accent Therapeutics $55 million up front to gain access to its drug discovery know-how in RNA-modifying protein biology.The biology of RNA modification is a relatively new field. Small molecule drugs that can inhibit cancer-linked enzymes and other proteins th...
Tags: Deals, Boston, Cancer, Trends, Startup, Venture Capital, Astrazeneca, Biotech, R&D, Partnership, Life Sciences, Oncology, Clinical Trials, Cambridge UK, Alliance, José Baselga


NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation

Our immune systems are designed to monitor for signs of foreign molecules, and among the first responses to such signals of potential danger are the formation of structures called inflammasomes.But the innate immune system’s natural inflammatory reaction, a protective mechanism meant to tackle any impending infection or injury, may also cause damaging inflammation in people with a wide range of diseases in which that lingering response causes chronic health problems.NodThera, one of a handful o...
Tags: Startups, Sofinnova Partners, Boston, Trends, Venture Capital, Biotech, Life Sciences, Inflammation, Seattle blog main, Seattle top stories, Boston blog main, Boston top stories, 5AM Ventures, F-Prime Capital, Clinical Trial, Nonalcoholic Steatohepatitis


Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs

Pliant Therapeutics is now a public company, raising $144 million from its IPO, plus more from a separate transaction with partner Novartis.South San Francisco-based Pliant priced its offering of 9 million shares at $16 apiece, which was the high end of its revised price range. When the biotech initially set IPO terms last week, it planned to sell 6.9 million shares in the range of $14 to $16 per share. On Tuesday, Pliant boosted the number of shares in the IPO but kept the price range. Pliant’...
Tags: Deals, Ipo, San Francisco, Trends, Novartis, Biotech, Life Sciences, Clinical Trials, National blog main, National top stories, San Francisco blog main, San Francisco top stories, Fibrosis, Nonalcoholic Steatohepatitis, Idiopathic Pulmonary Fibrosis, Pliant Therapeutics


Grail Plants a Seed in RTP, Pledges $100M Investment in New Site

Grail, a clinical-stage company developing cancer tests intended to detect early signs of the disease from a small blood sample, has agreed to invest $100 million in a new outpost planned for Research Triangle Park, NC.The new Grail site will have a laboratory and warehouse space, Gov. Roy Cooper announced Tuesday after an agreement was reached regarding an incentives package from the state. Menlo Park, CA-based Grail says the planned building will house a commercial laboratory focused on proce...
Tags: Deals, Startups, Cancer, Trends, Biotech, North Carolina, Illumina, Life Sciences, Clinical Trials, Guardant Health, Becton Dickinson, Menlo Park CA, Roy Cooper, Advanced Animal Diagnostics, National blog main, National top stories


Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact

Four years after Regeneron Pharmaceuticals and Intellia Therapeutics began working together to research the use of CRISPR/Cas9 to treat liver diseases, the partners are expanding their pact to bleeding disorders.The deal announced Monday covers the development of potential treatments for hemophilia, which stems from genetic mutations that lead to insufficient levels of blood clotting proteins. The revised alliance covers the joint development of potential treatments for both hemophilia A and B....
Tags: Deals, New York, Trends, Pfizer, Biotech, Crispr, Life Sciences, Clinical Trials, Gene Editing, John Leonard, Regeneron, Regeneron Pharmaceuticals, Gene Therapy, CRISPR/Cas9, BioMarin Pharmaceutical, Intellia Therapeutics


Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More

A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from throughout the country and around the world to check out the latest in cancer research.ASCO 2020 won’t be the Windy City gathering it usually is, but drug and diagnostics developers are still raring to share fresh data from their efforts in cancer i...
Tags: Startups, Ipo, Funding, Trends, Merck, Chicago, Alzheimer's Disease, Incubator, Stem Cells, Venture Capital, Machine Learning, Fda, National, Contraception, GlaxoSmithKline, Ai